- Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing Standards
- Oragenics, Inc. Files 10K and Provides Company Update
- Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion
- Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion
Key statistics
On Friday, Oragenics Inc (OGEN:ASQ) closed at 2.02, 102.00% above the 52 week low of 1.00 set on Apr 29, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 2.03 |
---|---|
High | 2.13 |
Low | 1.98 |
Bid | 1.92 |
Offer | 2.07 |
Previous close | 2.04 |
Average volume | 300.20k |
---|---|
Shares outstanding | 4.48m |
Free float | 3.44m |
P/E (TTM) | -- |
Market cap | 9.05m USD |
EPS (TTM) | -7.98 USD |
Data delayed at least 15 minutes, as of May 31 2024 21:10 BST.
More ▼